ArticleAmerican journal of hematology2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 80 citations in OpenAlex.
- One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.Annals of hematology · 2026Trial
- Trial
- KIR3DL1-HLA-Bw status in CML is associated with achievement of TFR: the POKSTIC trial, a multicenter observational study.Blood neoplasia · 2024Trial
- Article
- Is there a best frontline therapy in chronic myeloid leukemia?Haematologica · 2026Review
- From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.Leukemia · 2026Review
- Chronic myeloid leukemia: incorporation of recent advances into current treatment algorithms.Blood cancer journal · 2026Review
- SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Clinical lymphoma, myeloma & leukemia · 2026Review
- Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm.Clinical lymphoma, myeloma & leukemia · 2026Review
- Bibliometric analysis and recent trends on tyrosine kinase inhibitors in leukemia.Discover oncology · 2025Article
- Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML.Leukemia · 2025Article
- A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens.Cancer · 2025Review
- Treatment Cessation in Chronic Myeloid Leukemia: Evidence and Uncertainties.Hematological oncology · 2025Review
- Treatment free remission (TFR) in chronic myeloid leukemia-results, compliance and patterns of failure from a tertiary care cancer centre in India.Blood cancer journal · 2025Article
- Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.British journal of haematology · 2025Article
- Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions.European journal of haematology · 2025Review
- Clinical Features and T-Cell Repertoire of Chronic Myeloid Leukemia Patients Who Attempt Discontinuation of Tyrosine Kinase Inhibitors: The ISAC-TFR Study.Cancer medicine · 2025Article
- Management of chronic myeloid leukemia in 2025.Cancer · 2025Review
- Article
- Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase.Clinical lymphoma, myeloma & leukemia · 2025Article
Corrections and comments
- AssociatedDataset
Authors and funding
18 authors at 1 institution in 1 country.
Funding
Abstract
Tyrosine kinase inhibitors (TKIs) discontinuation in patients with Philadelphia-chromosome-positive chronic myeloid leukemia (Ph-positive CML) is increasingly considered. We aim to evaluate the outcome of patients with CML who discontinued TKIs, and determine the factors associated with differences in the success rates of treatment-free remission (TFR). Patients with Ph-positive CML treated between October 1999 and February 2017 who discontinued therapy were analyzed. A major molecular response (MMR) was defined as BCR-ABL1/ABL1 ratio on the International Scale ≤0.1%. TFR failure was defined as the loss of MMR on any single test. We analyzed TFR rates according to duration and depth of response, and conducted a multivariate analysis for factors associated with loss of MMR. Two-hundred and eighty-four patients were analyzed; 199 patients (70%) electively discontinued TKIs. At a median follow-up of 36 months (95% confidence interval, 32-40) after TKI discontinuation, 53 patients (19%) lost MMR. The estimated 5-year TFR rate was 79%. All but one patient regained MMR after resuming therapy. The estimated 5-year TFR rates were higher with MR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.